Royalty Pharma Investments 2019 ICAV

Insider Reports History

Location
New York, NY
Signature
Royalty Pharma Investments 2019 ICAV, By: /s/ Pablo G. Legorreta, Director
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Royalty Pharma Investments 2019 ICAV:

Company Role Class Num Shares Value Price $ Report Date Ownership
Epizyme, Inc. Director, 10%+ Owner Common Stock 22,666,667 $31,960,000 $1.41 31 Jan 2022 Direct

Insider Reports Filed by Royalty Pharma Investments 2019 ICAV

Symbol Company Period Transactions Value $ Form Type Role Filing Time
/report/000089924322005424-royalty-pharma-investments-2019-icav-2022-01-31 Epizyme, Inc. 31 Jan 2022 0 $0 3 Director, 10%+ Owner 09 Feb 2022, 15:30